Beijing Tiantan Biological Products Co Ltd
Research Beijing Tiantan Biological Products Co Ltd (600161.SS) on Bullrun: market cap CNY 24.44B, P/E 34.3, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker600161.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 24.44B
- P/E34.3
- Dividend yield1.2%
- Financial periodQ2 2026
- RevenueCNY 1.45B
- Net incomeCNY 173.04M
- Free cash flowCNY 150.39M
- Gross margin37.1%
Valuation Snapshot
latest market cap is CNY 24.44B; P/E is 34.3; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 34.33x versus a Healthcare sector median of 21.8x (57.5% above).
Latest dividend yield is 1.21% versus a Healthcare sector median of 2.4% (49.6% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 24.44B | 34.3 | 1.2% | 0.15 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.15 CNY, yield 1.2%.
About Beijing Tiantan Biological Products Co Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin;
ETFs that hold Beijing Tiantan Biological Products Co Ltd
US-listed ETFs
Beijing Tiantan Biological Products Co Ltd is held by 17 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Xtrackers Harvest CSI 300 China A-Shares ETF (ASHR) | 0.06% | 0.65% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Beijing Tiantan Biological Products Co Ltd's market cap?
Beijing Tiantan Biological Products Co Ltd's market capitalization is CNY 24.44B.
What is Beijing Tiantan Biological Products Co Ltd's P/E ratio?
Beijing Tiantan Biological Products Co Ltd's price-to-earnings (P/E) ratio is 34.3.
Does Beijing Tiantan Biological Products Co Ltd pay a dividend?
Beijing Tiantan Biological Products Co Ltd has a dividend yield of 1.2%.
What does Beijing Tiantan Biological Products Co Ltd do?
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally.